A Phase 1 interventional study of Lucerastat and Placebo in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study were to evaluate the safety and tolerability of lucerastat and to determine its pharmacokinetic profile after multiple dosing. Also, the potential effect of food on the pharmacokinetics of lucerastat was explored following a single dose of 500 mg.
The subjects were to be enrolled sequentially to three dose groups, starting with the lowest dose level. Subjects could participate in only one Group. Progression to an increased dose of lucerastat was permitted only after review of all data from the previous cohort suggested that it was safe to do so.
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
Drug: Lucerastat
Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
Drug: Lucerastat
Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
Drug: Lucerastat
Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
Drug: Lucerastat
Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
Drug: Placebo
Capsule for oral administration containing lucerastat
Also known as: OGT-923, ACT-434964, CDP923
Placebo capsules matching lucerastat capsules
Dose proportionality in lucerastat pharmacokinetics assessed by maximum plasma concentration (Cmax)
Cmax was used to assess dose proportionality across all dose groups
Time frame: PK blood samples were collected on Day 7, at pre-dose and at scheduled time points up to 48 hours after the morning dose
Dose proportionality in lucerastat pharmacokinetics assessed by area under the concentration-time curve (AUC)
AUC from time zero to infinity \[AUC(0-inf)\] was used to assess dose proportionality across all dose groups
Time frame: PK blood samples were collected on Day 7, at pre-dose and at scheduled time points up to 48 hours after the morning dose on Day 7
Terminal elimination half-life (t1/2)
t1/2 was calculated from the plasma concentrations-time curves of lucerastat after multiple doses
Time frame: PK blood samples were collected on Day 7, at pre-dose and at scheduled time points up to 48 hours after the morning dose on Day 7
Food effect on lucerastat pharmacokinetics assessed by Cmax
Potential food effect on pharmacokinetic parameters of lucerastat was tested by comparing Cmax in fed vs fasted state in the 500 mg cohort (cohort 2)
Time frame: PK blood samples were collected on Day 1, at pre-dose and at scheduled time points up to 12 hours after the morning dose
Food effect on lucerastat pharmacokinetics assessed by AUC
Potential food effect on pharmacokinetic parameters of lucerastat was tested by comparing AUC in fed versus fasted state in the 500 mg cohort (cohort 2)
Time frame: PK blood samples were collected on Day 1, at pre-dose and at scheduled time points up to 12 hours after the morning dose
Number of participants with adverse events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation subject, which did not necessarily have a causal relationship with the treatment
Time frame: From baseline up to Day 14 (end of study)
Change from baseline in haematology after multiple doses of lucerastat
Time frame: Up to Day 9
Change from baseline in clinical chemistry after multiple doses of lucerastat
Time frame: Up to Day 9
Change from baseline in heart rate after multiple doses of lucerastat
Time frame: Up to Day 9
Change from baseline in haematology after a single dose of lucerastat
Time frame: At 24 hours post dose
Change from baseline in clinical chemistry after a single dose of lucerastat
Time frame: At 24 hours post dose
Change from baseline in heart rate after a single dose of lucerastat
Time frame: At 24 hours post dose
Change from baseline in blood pressure after a single dose of lucerastat
Time frame: Up to 24 hours post dose
Change from baseline in electrocardiogram (ECG) variables after a single dose of lucerastat
Time frame: Up to 24 hours post dose
Stool frequency after multiple doses of lucerastat
Time frame: Every day up to Day 9
Change from baseline in body weight after multiple doses of lucerastat
Time frame: At Day 9
Plan to share: No
The record gives a start of Dec 2003, a primary completion of May 2004 and a completion of May 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat
Idorsia Pharmaceuticals Ltd. →